Top Story
Patient Outcomes & EngagementThe U.S. saw a record 107,941 drug overdose deaths in 2022, a slight rise from the previous year, signaling a potential stabilization after decades of increases, particularly during the COVID-19 pandemic. This data from the Centers for Disease Control and Prevention suggests a plateau in the [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/25/2024 04:46 PM ET
Processa Pharmaceuticals BCDA date announcement
BioCardia has an announcement scheduled for December 31, 2024 regarding their recent Phase 3 trial of CardiAMP (BCDA-02). The community is currently bullish on the prospects of progression, as the bulls outnumber bears by five [...]
Read More
04/25/2024 04:46 PM ET
Elicio Therapeutics ELTX date announcement
Now that the Phase 1/2 trial of ELI-002 - (AMPLIFY-7P) is completed, Elicio Therapeutics will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 60.9% chance of making it [...]
Read More
04/25/2024 04:46 PM ET
Vistagen Therapeutics VTGN results announcement
Vistagen Therapeutics provided an update to their Phase 2a trial for PH15. Our analysts provided the following summary:
"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo [...]
04/25/2024 04:46 PM ET
BeiGene Ltd. BGNE date announcement
BeiGene Ltd. already had seven catalyst announcements coming up, but they added another one today. It will be announcing top-line results for their recent Phase 1a trial for BGB‑15025 monotherapy and in combination with tislelizumab [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
